BriaCell to Participate at Upcoming Conferences and Appoints Senior R&D Director

BERKELEY, Calif. and VANCOUVER, British Columbia, May 11, 2021— BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announced that Dr. William V. Williams, President & CEO of BriaCell, is scheduled to participate in the following virtual conferences: • Benzinga …

BriaCell Announces Investor and Media Outreach Programs

BERKELEY, Calif. and VANCOUVER, British Columbia, April 15, 2021— BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that it has recently expanded its investor and media outreach platform in order to enhance communication with investors and increase investor awareness …

BriaCell Announces Closing of Over-Allotment Option in Connection with U.S. Public Offering, Bringing Total Gross Proceeds to US$28.7 Million

BERKELEY, Calif. and VANCOUVER, British Columbia, April 12, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announced that it has completed the sale of an additional 882,352 shares at the public offering price of US$4.24 …

BriaCell Therapeutics Presents Clinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021

Clinical and pathological data presented from the clinical trials of Bria-IMT™ alone and in combination with immune checkpoint inhibitors in advanced breast cancer indicates high responding subset with protracted progression-free survival: • Data suggests a link with cancer grade, disease control, and progression-free-survival in patients treated with Bria-IMT™. • Highest rate of disease control and …

BriaCell Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2021

• Clinical and pathological findings from clinical trial of the Bria-IMT™ regimen alone and in combination with immune checkpoint inhibitors in advanced breast cancer will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021, April 10-15 and May 17-21. • Pathological data of Bria-IMT and its potential link with disease control …

BriaCell Announces Closing of US$25 Million Public Offering

BERKELEY, Calif. and VANCOUVER, British Columbia, February 26, 2021— BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today closed its previously announced underwritten public offering in the United States. The Company offered 4,852,353 common units at a public offering price …

BriaCell Announces Pricing of US$25 Million Public Offering and Nasdaq Listing

BERKELEY, Calif. and VANCOUVER, British Columbia, February 23, 2021— BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announced the pricing of an underwritten public offering in the United States of 5,882,353 units, each unit consisting of one share of …

BriaCell Presents Clinical Data at 2021 Keystone Symposium

Clinical and pathological findings presented from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint inhibitors in advanced breast cancer: • Median overall survival of 12.5 months in patients with moderately-well differentiated tumors despite an average of 7 failed prior therapy regimens (versus 7.2-9.8 months of others). • Prolonged survival rates and …

BriaCell Announces Presentation at the 2021 Keystone Symposia Conference: Emerging Cell Therapies

• Clinical and pathological data from clinical trial of the Bria-IMT™ regimen alone or in combination with immune checkpoint inhibitors in advanced breast cancer will be presented at the Keystone Symposia, Jan. 25-27, 2021. BERKELEY, Calif. and VANCOUVER, British Columbia, January 12, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), …

BriaCell Presents Clinical Data at the 2020 San Antonio Breast Cancer Symposium®

Disease control and survival data is presented from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint inhibitors in advanced breast cancer: • Maximum tumor reduction and clinical benefit was observed in heavily pre-treated advanced breast cancer patients, particularly with moderately-well differentiated tumors. • Patients with moderately-well differentiated tumors had a higher …

Skip to content